Please login to the form below

Not currently logged in
Email:
Password:

TxCell

This page shows the latest TxCell news and features for those working in and with pharma, biotech and healthcare.

Syncona launches another cell therapy company, Treg specialist Quell

Syncona launches another cell therapy company, Treg specialist Quell

French biotech TxCell – which focuses on ‘CAR-Treg’ therapies designed to provide finely-tuned immunosuppression for indications like organ transplant and avoid broad immunosuppression that can cause infections and cancer – was

Latest news

  • Sangamo bulks up in cell therapy with TxCell acquisition Sangamo bulks up in cell therapy with TxCell acquisition

    Hopes to start cell-based immunotherapy trials next year. Sangamo has agreed a 72m deal to take control of French biotech TxCell, eyeing a regulatory T cell (Treg) platform that it ... By acquiring TxCell, Sangamo thinks it will be able to start trials

  • TxCell plans listing as EU biotech wakes up to IPOs

    Move follows UK allergy therapy developer Circassia's listing. The return of the biotech initial public offering (IPO) in 2013 was largely a US phenomenon, but France's TxCell is flying ... Ferring is paying 3m upfront for rights to Ovasave, and will be

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Deal Watch table for March 2014 Deal Watch table for March 2014

    138.5. TxCell/ Ferring. Collaboration, option,  licence. Ovasave - personalised cell-based immunotherapy for IBD (inc Crohn's disease, ulcerative colitis) (p2).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Zelluna appoints Miguel Forte as CEO Zelluna appoints Miguel Forte as CEO

    Prior to his new role, Forte has held roles for Bone Therapeutics, TxCell, the European Medicines Agency, and  UCB to name a few.

  • Bone Therapeutics strengthens clinical development team Bone Therapeutics strengthens clinical development team

    Forte arrives at Bone Therapeutics with over 20 years of industry experience, most recently as chief operating and medical officer at TxCell and before that as chair of the commercialisation committee

  • TxCell appoints François Myer as executive chairman TxCell appoints François Myer as executive chairman

    French biotech company TxCell has appointed François Meyer as its executive chairman as it completes a strategic realignment around its CAR-Treg research programmes. ... Stéphane Boissel, CEO of TxCell, said: “TxCell has now completed its strategic

  • Dr Li Zhou joins TxCell as cell engineering VP Dr Li Zhou joins TxCell as cell engineering VP

    Brings experience from Novartis and ZMKS. Valbonne, France-based biotech TxCell has appointed Dr Li Zhou as vice president of cell engineering with its research department. ... François Meyer, head of research at TxCell, said: “With this key

  • TxCell appoints global scientific advisory board TxCell appoints global scientific advisory board

    French biotechnology firm TxCell has appointed Prof Zelig Eshar, Prof Chiara Bonini and Dr Bernard Malissen to its newly-formed scientific advisory board. ... As members of the board, they will be responsible for monitoring and guiding the research and

More from appointments
Approximately 3 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
EPG Health

REACH, ENGAGE & MEASURE - Accomplish meaningful HCP engagement via Medthority, our trusted independent medical website. Support education and treatment...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics